ObjectiveTo evaluate the efficacy and safety of Xiaoji Hufei Formula in protecting children with close contact exposure to influenza， and to provide reference and evidence-based support for better clinical prevention and treatment of influenza in children. MethodsA multicenter， prospective， non-randomized， parallel， controlled trial was conducted from October 2021 to May 2022 in five hospitals， including Dongfang Hospital of Beijing University of Chinese Medicine. Confirmed influenza cases and influenza-like illness （ILI） cases were collected， and eligible children with close contact exposure to these cases were recruited in the outpatient clinics. According to whether the enrolled close contacts were willing to take Xiaoji Hufei formula for influenza prevention， they were assigned to the observation group （108 cases） or the control group （108 cases）. Follow-up visits were conducted on days 7 and 14 after enrollment. The primary outcomes were the incidence of ILI and the rate of laboratory-confirmed influenza. Secondary outcomes included traditional Chinese medicine （TCM） symptom score scale for influenza， influenza-related emergency （outpatient） visit rate， influenza hospitalization rate， and time to onset after exposure to influenza cases. ResultsA total of 216 participants were enrolled， with 108 in the observation group and 108 in the control group. Primary outcomes： （1） Incidence of ILI： The incidence was 12.0% （13/108） in the observation group and 23.1% （25/108） in the control group， with the observation group showing a significantly lower incidence （χ²=4.6， P<0.05）. （2） Influenza confirmation rate： 3.7% （4/108） in the observation group and 4.6% （5/108） in the control group， with no statistically significant difference. Secondary outcomes： （1） TCM symptom score scale： after onset， nasal congestion and runny nose scores differed significantly between the two groups （P<0.05）， while other symptoms such as fever， sore throat， and cough showed no significant differences. （2） Influenza-related emergency （outpatient） visit rate： 84.6% （11 cases） in the observation group and 96.0% （24 cases） in the control group， with no significant difference. （3） Time to onset after exposure： The median onset time after exposure to index patients was 7 days in the observation group and 4 days in the control group， with a statistically significant difference （P<0.05）. ConclusionIn previously healthy children exposed to infectious influenza cases under unprotected conditions， Xiaoji Hufei formula prophylaxis significantly reduced the incidence of ILI. Xiaoji Hufei Formula can be recommended as a specific preventive prescription for influenza in children.

ObjectiveTo evaluate the efficacy and safety of Xiaoji Hufei Formula in protecting children with close contact exposure to influenza， and to provide reference and evidence-based support for better clinical prevention and treatment of influenza in children. MethodsA multicenter， prospective， non-randomized， parallel， controlled trial was conducted from October 2021 to May 2022 in five hospitals， including Dongfang Hospital of Beijing University of Chinese Medicine. Confirmed influenza cases and influenza-like illness （ILI） cases were collected， and eligible children with close contact exposure to these cases were recruited in the outpatient clinics. According to whether the enrolled close contacts were willing to take Xiaoji Hufei formula for influenza prevention， they were assigned to the observation group （108 cases） or the control group （108 cases）. Follow-up visits were conducted on days 7 and 14 after enrollment. The primary outcomes were the incidence of ILI and the rate of laboratory-confirmed influenza. Secondary outcomes included traditional Chinese medicine （TCM） symptom score scale for influenza， influenza-related emergency （outpatient） visit rate， influenza hospitalization rate， and time to onset after exposure to influenza cases. ResultsA total of 216 participants were enrolled， with 108 in the observation group and 108 in the control group. Primary outcomes： （1） Incidence of ILI： The incidence was 12.0% （13/108） in the observation group and 23.1% （25/108） in the control group， with the observation group showing a significantly lower incidence （χ²=4.6， P<0.05）. （2） Influenza confirmation rate： 3.7% （4/108） in the observation group and 4.6% （5/108） in the control group， with no statistically significant difference. Secondary outcomes： （1） TCM symptom score scale： after onset， nasal congestion and runny nose scores differed significantly between the two groups （P<0.05）， while other symptoms such as fever， sore throat， and cough showed no significant differences. （2） Influenza-related emergency （outpatient） visit rate： 84.6% （11 cases） in the observation group and 96.0% （24 cases） in the control group， with no significant difference. （3） Time to onset after exposure： The median onset time after exposure to index patients was 7 days in the observation group and 4 days in the control group， with a statistically significant difference （P<0.05）. ConclusionIn previously healthy children exposed to infectious influenza cases under unprotected conditions， Xiaoji Hufei formula prophylaxis significantly reduced the incidence of ILI. Xiaoji Hufei Formula can be recommended as a specific preventive prescription for influenza in children.

Traditional Chinese Medicine (TCM), as a treasure of the Chinese nation, plays a significant role in maintaining public health. In 2019, the Central Committee of the Communist Party of China and the State Council proposed for the first time the establishment of a TCM registration and evaluation evidence system that integrates TCM theory, "personal experience" and clinical trials (referred to as the "Three-in-One" System) to promote the inheritance and innovation of TCM. Subsequently, the National Medical Products Administration issued several guiding principles to advance the improvement and implementation of this system. Owing to the complexity of its implementation, there are still differing understandings within the TCM industry regarding the positioning of the "Three-in-One" Registration and Evaluation Evidence System, as well as the connotation and value orientation of the "personal experience." To address this, Academician WANG Qi, President of the TCM Association, China International Exchange and Promotion Association for Medical and Healthcare and TCM master, led a group of academicians, TCM masters, TCM pharmacology experts and clinical TCM experts to convene a "Seminar on Promoting the Implementation of the ′Three-in-One′ Registration and Evaluation Evidence System for Chinese Medicinals." Through extensive discussions, an expert consensus was formed, clarifying the different roles of the TCM theory, "personal experience" and clinical trials within the system. It was further emphasized that the "personal experience" is the core of this system, and its data should be derived from clinical practice scenarios. In the future, the improvement of this system will require collaborative efforts across multiple fields to promote the high-quality development of the Chinese medicinal industry.

Humans ; Urinary Bladder Neoplasms/pathology* ; Carcinoma, Transitional Cell/pathology* ; Genetic Markers ; Biomarkers, Tumor/genetics* ; Urothelium/pathology*

Contrast-induced encephalopathy(CIE)is a rare neurological complication of the intravascular application of a contrast media.The clinical manifestation of CIE which is easily misdiagnosed in clinical is not specific.Recently,with the extensive development of interventional diagnosis and therapy in different disciplines,case report of CIE patient is increasing yearly.At present,there is not a uniform diagnosis and treatment standard for CIE in China and abroad.Chinese Federation of Interventional Clinical Neurosciences organized relevant experts in China and developed the expert consensus,to provide suggestions and references for clinicians at all levels to prevent,identify and treat CIE.

Objective To explore Professor Wu Liqun's medication law for treating tic disorders in children.Methods Medical records of tic disorders children treated by Professor Wu Liqun from September 2016 to October 2022 were collected,and a database was established.SPSS Statistics 23 was used for frequency statistics,and Liquorice software was used for multi-scale backbone network analysis and multi-layer core network analysis to summarize the medication law.Results Totally 709 medical records were included,involving 834 prescriptions and 203 kinds of Chinese materia medica.The drug categories were mostly tonic drugs,heat-clearing drugs,and liver-pacifying and wind-relieving drugs.The properties of the drugs were mainly warming,cold,and mild,and the meridians were mostly in the lung,liver,and spleen meridians.Complex network analysis showed that the core prescription consisted of 20 kinds of Chinese materia medica,such as Angelicae Sinensis Radix,Paeoniae Radix Alba,Chuanxiong Rhizoma,Codonopsis Radix,and 30 groups of commonly used medicine pairs and commonly used medicines with different symptoms and commodities were obtained.Conclusion Professor Wu Liqun's treatment for tic disorders in children focuses on treating"liver wind",evacuating external wind to cut off the course of the disease,soothing the liver and subduing yang to extinguish internal wind,paying attention to regulating liver qi,nourishing yin and soothing the liver,nourishing blood and extinguishing wind.

Objective To analyze the allocation and utilization efficiency of hospital beds from 2017-2021,and to provide a reference for the optimal allocation of hospital bed resources in Shenzhen.Methods Descriptive statistics method,bed efficiency index and bed utilization model were used to evaluate the hospital bed allocation and utilization efficiency of Shenzhen hospitals for 5 years.Results The number of beds in Shenzhen increased every year,with the highest growth rate of 21.54%,and the number of beds per 1000 resident population increased from 3.04 in 2017 to 3.25 in 2021.From the bed efficiency index,all three types of hospitals(general hospitals,specialized hospitals,traditional Chinese medicine hospitals)in Shenzhen are operating at low efficiency.Government-run hospitals are operating at high efficiency except for 2020,while socially-run hospitals are operating at low efficiency for five years,with bed efficiency indexs below 0.4.From the bed utilization model,Shenzhen general hospitals are turnover hospitals,Chinese medicine hospitals are bed-pressure hospitals for the first two years and then turn into efficiency hospitals,and specialty hospitals are idle hospitals.The government-run hospitals were efficient hospitals for 5 years,while the socially-run hospitals were idle hospitals for 5 years.Conclusion It is necessary to reasonably allocate health resources to increase the number of beds,improve the ability of hospitals to admit and absorb patients,and improve the operational efficiency of beds;the improvement and upgrading of beds in various types of hospitals should be tailored to local conditions to promote the realization of the continuity of care by integrating the concept of health care.

Objective:To estimate the scale,expenditure and financing structure of potentially preventable hospitalization(PPH)for diabetes in Shenzhen,and provide data support for improving the utilization efficiency of medical and health resources.Methods:The System of Health Account 2011 was used to calculate the status of PPH for diabetes in Shenzhen and its cost scale and structure.Results:In 2019-2022,there will be a total of 441 426 avoidable hospital admissions for diabetes,hypertension,angina,influenza and pneumonia and dehydration and gastroenteritis,which cumulatively account for approximately 70.00%of admissions.The cost of hospitalization could be avoided by 525 028.06 million yuan,accounting for 6.18%of the total costs.The out-of-pocket costs were 1 762.724 4 million yuan,accounting for 33.57%of the total avoidable hospitalization costs.The out-of-pocket payment of angina pectoris,gangrene and rheumatic heart disease were higher and the proportion of out-of-pocket costs was larger.Conclusion:The large scale of hospital can be avoided in Shenzhen,and the waste of medical resources caused by unreasonable hospitalization is serious.The level of primary health care should be improved,the behavior of doctors should be regulated,the role of intervention in diseases of key populations should be increased,and the system of reimbursement of health insurance should be optimized.

Currently the diagnosis and bed cost accounting methods reflecting the overall level of regional public hospitals have not yet matured.It explores an relatively scientific and practically accounting method based on the financial annual report of public hospitals to gain the per visit costs and per bed-day costs in a certain area,which can help the decisions of the health administra-tive department.The data from a public hospital owned by Shenzhen Health Commission is used for feasibility verification.It aims to promote the innovation and application of cost accounting method of public hospitals,and for give play to the auxiliary deci-sion-making role for the health administrative department,promote the improvement of the fiscal investment mechanism,and help public hospitals with high-quality development.

Objective:To estimate the scale,expenditure and financing structure of potentially preventable hospitalization(PPH)for diabetes in Shenzhen,and provide data support for improving the utilization efficiency of medical and health resources.Methods:The System of Health Account 2011 was used to calculate the status of PPH for diabetes in Shenzhen and its cost scale and structure.Results:In 2019-2022,there will be a total of 441 426 avoidable hospital admissions for diabetes,hypertension,angina,influenza and pneumonia and dehydration and gastroenteritis,which cumulatively account for approximately 70.00%of admissions.The cost of hospitalization could be avoided by 525 028.06 million yuan,accounting for 6.18%of the total costs.The out-of-pocket costs were 1 762.724 4 million yuan,accounting for 33.57%of the total avoidable hospitalization costs.The out-of-pocket payment of angina pectoris,gangrene and rheumatic heart disease were higher and the proportion of out-of-pocket costs was larger.Conclusion:The large scale of hospital can be avoided in Shenzhen,and the waste of medical resources caused by unreasonable hospitalization is serious.The level of primary health care should be improved,the behavior of doctors should be regulated,the role of intervention in diseases of key populations should be increased,and the system of reimbursement of health insurance should be optimized.